DOCSLIB.ORG

2021 Il Mmai

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 Il Mmai Blue Cross Community MMAI (Medicare-Medicaid Plan)SM 2021 List of Covered Drugs (FORMULARY) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File ID: 00021147 Effective January 2021 For more recent information or other questions, contact us at 1-877-723-7702 (TTY 711). We are available seven (7) days a week. Our call center is open Monday-Friday 8:00 a.m. - 8:00 p.m. Central time. On weekends and Federal holidays, voice messaging is available. If you leave a voice message, a Member Services representative will return your call no later than the next business day. Or visit http://www.bcbsil.com/mmai Updated on 08/16/2021 H0927_ILCOMP21 Accepted 234941.0821 Blue Cross Community MMAI 2021 LIST OF COVERED DRUGS Blue Cross Community MMAISM | 2021 List of Covered Drugs (Formulary) Introduction This document is called the List of Covered Drugs (also known as the Drug List). It tells you which prescription drugs and over-the-counter drugs and items are covered by Blue Cross Community MMAI. The Drug List also tells you if there are any special rules or restrictions on any drugs covered by Blue Cross Community MMAI. Key terms and their definitions appear in the last chapter of theMember Handbook. Table of Contents A. Disclaimers ................................................................................................................................................... i B. Frequently Asked Questions (FAQ) ......................................................................................................... iv B1. What prescription drugs are on the List of Covered Drugs? (We call the List of Covered Drugs the “Drug List” for short.) .............................................................................................................iv B2. Does the Drug List ever change? ..........................................................................................................iv B3. What happens when there is a change to the Drug List? ..................................................................... v B4. Are there any restrictions or limits on drug coverage or any required actions to take to get certain drugs? ........................................................................................................................................vi B5. How will you know if the drug you want has limits or if there are required actions to take to get the drug? ..........................................................................................................................................vi B6. What happens if we change our rules about some drugs (for example, prior authorization (approval), quantity limits, and/or step therapy restrictions)? ................................................................vi B7. How can you find a drug on the Drug List? ..........................................................................................vii B8. What if the drug you want to take is not on the Drug List? ...................................................................vii B9. What if you are a new Blue Cross Community MMAI member and can’t find your drug on the Drug List or have a problem getting your drug? ...................................................................................vii B10. Can you ask for an exception to cover your drug? ..............................................................................viii B11. How can you ask for an exception? .......................................................................................................ix B12. How long does it take to get an exception? ...........................................................................................ix B13. What are generic drugs? .......................................................................................................................ix B14. What are OTC drugs? ............................................................................................................................ix B15. Does Blue Cross Community MMAI cover non-drug OTC products? ..................................................ix B16. What is your copay? ..............................................................................................................................ix B17. What are drug tiers? .............................................................................................................................. x If you have questions, please call Blue Cross Community MMAI at 1-877-723-7702 (TTY 711). We are available seven (7) days a week. Our call center is open Monday-Friday 8:00 a.m. - 8:00 p.m. Central time. On weekends and Federal holidays, voice messaging is available. If you leave a voice message, a Member Services representative will return your call no later than the next business day. The call is free. For more information, visit http://www.bcbsil.com/mmai. Blue Cross Community MMAI 2021 LIST OF COVERED DRUGS C. Overview of the List of Covered Drugs ................................................................................................... xi C1. Drugs Grouped by Medical Condition .................................................................................................xiv D. Index of Covered Drugs ......................................................................................................................... 103 If you have questions, please call Blue Cross Community MMAI at 1-877-723-7702 (TTY 711). We are available seven (7) days a week. Our call center is open Monday-Friday 8:00 a.m. - 8:00 p.m. Central time. On weekends and Federal holidays, voice messaging is available. If you leave a voice message, a Member Services representative will return your call no later than the next business day. The call is free. For more information, visit http://www.bcbsil.com/mmai. Blue Cross Community MMAI 2021 LIST OF COVERED DRUGS A. Disclaimers This is a list of drugs that members can get in Blue Cross Community MMAI. • Blue Cross Community MMAI is a health plan that contracts with both Medicare and Illinois Medicaid to provide benefits of both programs to enrollees. • The List of Covered Drugs and/or pharmacy and provider networks may change throughout the year. We will send you a notice before we make a change that affects you. • ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1-877-723-7702 (TTY 711). We are available seven (7) days a week. Our call center is open Monday-Friday 8:00 a.m. - 8:00 p.m. Central time. On weekends and Federal holidays, voice messaging is available. If you leave a voice message, a Member Services representative will return your call no later than the next business day. The call is free. • ATENCIÓN: Si habla español, los servicios de asistencia lingüística están a su disposición sin costo alguno para usted. Llame al 1-877-723-7702 (TTY 711). Estamos a su disposición los siete (7) días de la semana. Nuestra central telefónica está abierta de lunes a viernes de 8:00 a. m. a 8:00 p. m., hora del centro. Para los fines de semana y días feriados federales, está disponible el servicio de mensajes de voz. Si deja un mensaje de voz, un representante de Atención al Asegurado le devolverá la llamada antes del próximo día laborable. • You can get this document for free in other formats, such as large print, braille, or audio. Call 1-877-723-7702 (TTY 711). We are available seven (7) days a week. Our call center is open Monday-Friday 8:00 a.m. - 9:00 p.m. Central time. On weekends and Federal holidays, voice messaging is available. If you leave a voice message, a Member Services representative will return your call no later than the next business day. The call is free. • You can request to always have your materials sent to you in the language and/or format (such as large print, braille, or audio) that you need. Call 1-877-723-7702 (TTY 711). Once requested, Member Services will always send you materials in your chosen language and/or format until you request to have it changed. This service is free. If you have questions, please call Blue Cross Community MMAI at 1-877-723-7702 (TTY 711). We are available seven (7) days a week. Our call center is open Monday-Friday 8:00 a.m. - 8:00 p.m. Central time. On weekends and Federal holidays, voice messaging is available. If you leave a voice message, a Member Services representative will return your call no later than the next business day. The call is free. For more information, visit http://www.bcbsil.com/mmai. i Blue Cross Community MMAI 2021 LIST OF COVERED DRUGS Blue Cross and Blue Shield of Illinois complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Blue Cross and Blue Shield of Illinois does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. Blue Cross and Blue Shield of Illinois: • Provides free aids and services to people with disabilities to communicate effectively with us, such as: ○ Qualified sign language interpreters ○ Written information in other formats (large print, audio, accessible electronic formats, other formats) • Provides free language services to people whose primary language is not English, such as: ○ Qualified interpreters ○ Information written in other languages If you need these services, contact Civil Rights Coordinator. If you believe that Blue Cross and Blue Shield of Illinois has failed to provide these
Load more

Recommended publications
  • Aminoindanesthe Next Wave of Legal Highs?
    Drug Testing Review and Analysis Received: 23 May 2011 Accepted: 24 May 2011 Published online in Wiley Online Library: 11 July 2011 (www.drugtestinganalysis.com) DOI 10.1002/dta.318 Aminoindanes – the next wave of ‘legal highs’? P.D. Sainsbury,a A.T. Kicman,a R.P. Archer,b L.A. Kinga and R.A. Braithwaitea∗ Due to its closed ring system, 2-aminoindane is a conformationally rigid analogue of amphetamine. Internet websites offering synthetic compounds as ‘research chemicals’ have recently been advertising 5,6-methylenedioxy-2-aminoindane (MDAI), 5, 6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), 5-iodo-2-aminoindane (5-IAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI). The chemistry, pharmacology, and toxicological aspects of this new class of psychoactive substances are reviewed, as these could become the next wave of ‘legal highs’. Copyright c 2011 John Wiley & Sons, Ltd. Keywords: aminoindanes; legal highs; MDAI; MDMAI; 5-IAI; MMAI; serotonin. Introduction Pharmacology Although Solomons and Sam reported in 1973 that the aminoin- Historically, the terms ‘legal highs’ and ‘herbal highs’ referred to danes possessed significant bronchodilating and analgesic blends of psychoactive plants or fungi that could be smoked properties,[2] more recent research points to the aminoindanes as or ingested to induce dissociative effects and hallucinations. having potent effects on serotonin release and re-uptake. A num- These terms, however, have more recently been widened to ber of studies undertaken in the late 1980s and early 1990s con- describe an extensive and growing range of entirely synthetic cerning Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) substances that have become popular as recreational drugs of also included a comparison with a number of MDMA analogues abuse; this coincides with a period of intense media interest that incorporated an indane ring.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • 2021 Il Mmai
    MeridianComplete (Medicare-Medicaid Plan) 2021 List of Covered Drugs (Formulary) Formulary ID: 21425 Version Number: 21 Updated on 8/24/2021. For more recent information or other questions, contact us at 1-855-580-1689 (TTY users should call 711). Representatives are available Monday-Friday, 8 a.m. to 8 p.m. to assist you. On weekends and on state or federal holidays, you may be asked to leave a message. Your call will be returned within the next business day. Or visit corp.mhplan.com/en/member/illinois/complete/. H6080_MMP_61396E_Accepted DIR053819ET00 H6080_MMP_61396E_Approved MeridianComplete | 2021 List of Covered Drugs (Formulary) Introduction This document is called the List of Covered Drugs (also known as the Drug List). It tells you which prescription drugs and over-the-counter drugs and items are covered by MeridianComplete (Medicare-Medicaid Plan). The Drug List also tells you if there are any special rules or restrictions on any drugs covered by MeridianComplete. Key terms and their definitions appear in the last chapter of the Member Handbook. Table of Contents A. Disclaimers ............................................................................................................................... 3 B. Frequently Asked Questions (FAQ) .......................................................................................... 4 B1. What prescription drugs are on the List of Covered Drugs? (We call the List of Covered Drugs the “Drug List” for short.) ........................................................................................
    [Show full text]
  • Drugs and New Potentially Dangerous Chemical Substances, with a Brief Review of the Problem
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL & SCIENCE EDUCATION 2016, VOL. 11, NO. 14, 6697-6703 OPEN ACCESS Approach to Classifying “Design” Drugs and New Potentially Dangerous Chemical Substances, With a Brief Review of the Problem Azat R. Asadullina, Elena Kh. Galeevab, Elvina A. Achmetovaa and Ivan V. Nikolaevb aBashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa, RUSSIA; bRepublican Narcological Dispensary No.1 of the Ministry of Health of the Republic of Bashkortostan, Ufa, RUSSIA ABSTRACT The urgency of this study has become vivid in the light of the growing problem of prevalence and bBPHFuse Republican of new synthetic Narcological drug types. DispensaryLately there has No.1 been of a thetendency Ministry of expanding of Health the rangeof the of psychologically active substances (PAS) used by addicts with the purpose of their illegal taking. RepublicThe aim of Bashkortostan,of this research is anPushkin attempt str.,of systematizing 119/1, Ufa, and RB. classifying “design” drugs according to their chemical structure, neurochemical mechanisms of action and clinical manifestations. As a result, we have found that they can be divided into ten big groups. This classification will allow to better arrange new clinical phenomenology in modern addictology. This paper would be useful for psychiatrists, experts in narcology, as well as for personnel of institutions and agencies engaged in anti-drug activity. KEYWORDS ARTICLE HISTORY Opiates, cannabinoids, cathinones, tryptamine, Received 20 April 2016 cocaine, pregabalin, new “design” drugs, Revised 28 May 2016 classification Accepted 29 Мау 2016 Introduction Urgency of the problem Recently, the sphere of illegal turnover of narcotic substances has shown an apparent trend of producing the so-called “design drugs” (DN): new potentially dangerous psychologically active substances (NPDPAS) obtained by means of chemical synthesis, possessing a high narcotic effect and manufactured with the CORRESPONDENCE Azat R.
    [Show full text]
  • 2-Aminoindan and Its Ring-Substituted Derivatives Interact With
    LJMU Research Online Halberstadt, AL, Brandt, SD, Walther, D and Baumann, MH 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors http://researchonline.ljmu.ac.uk/id/eprint/10335/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Halberstadt, AL, Brandt, SD, Walther, D and Baumann, MH (2019) 2- Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors. Psychopharmacology. ISSN 0033-3158 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ 2-Aminoindan and its Ring-Substituted Derivatives Interact with Plasma Membrane Monoamine Transporters and
    [Show full text]
  • Novel Hallucinogens and Plant-Derived Highs
    Novel Hallucinogens and Plant-Derived Highs Emily Dye Forensic Chemist Special Testing and Research Laboratory Drug Enforcement Administration Outline • Hallucinogens • Plant-Derived Highs – 2C Compounds – Kratom – NBOMe Compounds – Fly Agaric Mushrooms – DOX Compounds – Kava Kava – Kanna • Empathogens – Aminoindanes – APDB – APB DEA Special Testing and Research Laboratory Emerging Trends Program 2C Compounds • Psychedelic phenethylamines • Synthesized by Alexander Shulgin – Published in PiHKAL • 27 known compounds – Most common: 2C-C, 2C-B, and 2C-I DEA Special Testing and Research Laboratory Emerging Trends Program 2C Compounds DEA Special Testing and Research Laboratory Emerging Trends Program 2C-B-FLY • Psychedelic phenethylamine • Synthesized by Aaron Monte www.erowid.org DEA Special Testing and Research Laboratory Emerging Trends Program Bromo-DragonFLY • Psychedelic phenethylamine • Synthesized in the lab of David Nichols • Deaths associated with misrepresentation as 2C-B-FLY www.erowid.org DEA Special Testing and Research Laboratory Emerging Trends Program NBOMe Compounds • Hallucinogenic phenethylamines • Synthesized by Heim, et al. • Isomers can be distinguished via RT and MS DEA Special Testing and Research Laboratory Emerging Trends Program Name R1 R2 R3 R4 Name R1 R2 R3 R4 25B-NB2OMe Br OCH3 H H 25N-NB2OMe NO2 OCH3 H H 25B-NB3OMe Br H OCH3 H 25N-NB3OMe NO2 H OCH3 H 25B-NB4OMe Br H H OCH3 25N-NB4OMe NO2 H H OCH3 25C-NB2OMe Cl OCH3 H H 25P-NB2OMe CH2CH2CH3 OCH3 H H 25C-NB3OMe Cl H OCH3 H 25P-NB3OMe CH2CH2CH3 H OCH3 H 25C-NB4OMe
    [Show full text]
  • Download Product Insert (PDF)
    Product Information 5-MAPDB (hydrochloride) Item No. 14111 Formal Name: 1-(2,3-dihydrobenzofuran-5- yl)-N-methylpropan-2-amine, monohydrochloride H MF: C12H17NO • HCl N FW: 227.7 • HCl Purity: ≥98% Stability: ≥2 years at -20°C O Supplied as: A crystalline solid λ UV/Vis.: max: 232, 287 nm Laboratory Procedures For long term storage, we suggest that 5-MAPDB (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. 5-MAPDB (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the 5-MAPDB (hydrochloride) in the solvent of choice. 5-MAPDB (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of 5-MAPDB (hydrochloride) in ethanol and DMSO is approximately 20 mg/ml and approximately 10 mg/ml in DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of 5-MAPDB (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of 5-MAPDB (hydrochloride) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day. 5-MAPDB is an entactogen belonging to the amphetamine and the phenethylamine classes.1 It is structurally related to MDMA and the MDA analog, 5-APDB.
    [Show full text]
  • Development of Chemical Sensors for Rapid Identification of Amphetamine-Related New Psychoactive Substances
    Development of Chemical Sensors for Rapid Identification of Amphetamine-Related New Psychoactive Substances Kathryn Emily Kellett Submitted to the University of Hertfordshire in partial fulfilment of the requirements of the degree of Doctor of Philosophy. Supervisors: Dr. Jacqueline L. Stair, Dr. Suzanne Fergus, Dr. Stewart B. Kirton and Prof. Andrew J. Hutt Department of Pharmacy, School of Life and Medical Sciences, University of Hertfordshire November 2016 Abstract A molecular receptor for mephedrone, an amphetamine-like NPS, was developed using host-guest chemistry and pharmacophoric design. The in-field detection of new psychoactive substances (NPS) is an area that has garnered considerable attention in the last few years. With the continuously expanding number of NPS on the market, traditional detection mechanisms lack the selectivity needed. In this project a new methodology has been developed for the design of host molecules for use in in-field detection, based on biomimetic design. To understand what a sensory molecular needs to be selective against, GC-MS and HPLC analysis were employed to identify and quantify thirteen aminoindane internet samples. It was found that the composition of internet samples varies greatly in terms of concentration of active ingredient, with a range of 17-95 % w/w of active ingredient identified. It was also found that caffeine was the most common cutting agent with a range of 27.7-30.2 % w/w identified. This highlights the need for both selectivity and sensitivity in detection mechanisms. Using the principles of biomimetic design, a methodology for the treatment of protein-ligand interactions was developed. Protein-ligand binding data collected from the Protein Databank was analysed for mephedrone related structures and common cutting agents, identified through aminoindane internet sample analysis and literature sources.
    [Show full text]
  • New Psychoactive Substances (NPS)
    New Psychoactive Substances (NPS) LGC Quality Reference ISO 9001 ISO/IEC 17025 ISO Guide 34 materials GMP/GLP ISO 13485 2019 ISO/IEC 17043 Science for a safer world LGC offers the most extensive and up-to-date range of New LGC is a global leader in Psychoactive Substances (NPS) measurement standards, reference materials. reference materials, laboratory services and proficiency testing. With 2,600 professionals working When you make a decision using The challenge The LGC response We are the UK’s in 21 countries, our analytical our resources, you can be sure it’s designated National measurement and quality control based on precise, robust data. And New Psychoactive Substances In response to the ever-expanding LGC Standards provides the widest Measurement services are second-to-none. together, we’re creating fairer, safer, (NPS) continue to be identified, range of NPS being developed, LGC range of reference materials Institute for chemical more confident societies worldwide. and it appears that moves by the has produced a comprehensive available from any single supplier. and bioanalytical As a global leader, we provide the United Nations and by individual range of reference materials that We work closely with leading widest range of reference materials lgcstandards.com countries to control lists of meet the rapidly changing demands manufacturers to provide improved measurement. available from any single supplier. named NPS may be encouraging of the NPS landscape. Many of access to reference materials, the development of yet further these products are produced under with an increasingly large range variants to avoid these controls. the rigorous quality assurance of parameters, for laboratories standards set out in ISO Guide 34.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information MMAI (hydrochloride) Item No. 13895 CAS Registry No.: 132980-17-7 Formal Name: 2,3-dihydro-5-methoxy-6-methyl-1H- inden-2-amine, monohydrochloride O MF: C H NO • HCl 11 15 NH2 FW: 213.7 Purity: ≥98% Stability: ≥2 years at -20°C • HCl Supplied as: A crystalline solid λ UV/Vis.: max: 284 nm Laboratory Procedures For long term storage, we suggest that MMAI (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. MMAI (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the MMAI (hydrochloride) in the solvent of choice. MMAI (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of MMAI (hydrochloride) in these solvents is approximately 0.5, 20, and 1 mg/ml, repsectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of MMAI (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of MMAI (hydrochloride) in PBS, pH 7.2, is approximately 0.2 mg/ml. We do not recommend storing the aqueous solution for more than one day. MMAI is a psychoactive aminoindan which can be found in recreational drug mixtures.1 It potently inhibits serotonin uptake (IC50 = 212 nM) and stimulates its release without inducing the neurotoxicity induced by 3,4-methylenedioxy methamphetamine and similar compounds.2,3 This product is intended for forensic and research applications.
    [Show full text]
  • 1 Pharmacological Profile of Mephedrone Analogs and Related New Psychoactive Substances Dino Luethia, Karolina E. Kolaczynskaa
    Pharmacological profile of mephedrone analogs and related new psychoactive substances Dino Luethia, Karolina E. Kolaczynskaa, Luca Doccia, Stephan Krähenbühla, Marius C. Hoenerb, Matthias E. Liechtia aDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland bNeuroscience Research, pRED, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland Running title: Mephedrone-like designer drugs *Corresponding author: Prof. Dr. med. Matthias E. Liechti, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Hebelstrasse 2, Basel, CH-4031, Switzerland. Tel: +41 61 328 68 68; Fax: +41 61 265 45 60; E-mail: [email protected] Word count: Manuscript: 3842, Abstract: 222, References: 59, Tables: 2, Figures: 3 1 Abstract Background: Mephedrone is a synthetic cathinone and one of the most popular recreationally used new psychoactive substances. The aim of the present study was to characterize the in vitro pharmacology of novel analogs of mephedrone and related newly emerged designer stimulants. Methods: We determined norepinephrine, dopamine, and serotonin transporter inhibition potencies and monoamine release in transporter-transfected human embryonic kidney 293 cells. We also assessed monoamine receptor and transporter binding affinities. Results: Mephedrone analogs potently inhibited the norepinephrine transporter and, with the exception of 3-methylmethcathinone (3-MMC), inhibited the serotonin transporter more potently than the dopamine transporter. Similar to classic amphetamines, mephedrone analogs were substrate-type monoamine releasers. 5-(2-Aminopropyl)indole (5-IT) was a highly potent monoamine transporter inhibitor and a releaser of dopamine and serotonin. 4- Methylamphetamine (4-MA) mediated efflux of all three monoamines and inhibited the serotonin transporter more potently than the dopamine transporter, unlike amphetamine.
    [Show full text]
  • P-Methylthioamphetamine Is a Potent New Non-Neurotoxic Serotonin-Releasing Agent
    Journalof Pharmacology229, (1992)31-38 31 1992ElsevierSciencePublishersB.V.All rights reserved 0014-2999/92/$05.(10 '52790 p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent Xuemei Huang, Danuta Marona-Lewicka and David E. Nichols Deportmentof Pharmacologandy Toxicologyand, Deportmentof M.edicinal_7_emisttyand Pharmacognosy,PurdueUnit'ersity, Schoolof PharmacyandPharmacalSciences,WestLaJ_tyetteIN, 47007,USA Received 14May I992, revised MS received 2 September 1992, accepted 8 September 1992 p-Methylthioamphetamine (MTA), was compared to p-chloroamphctamine (PCA) in a number of pharmacological assays. MTA was about 2-fold more potent than PCA at inhibiting synaptosomal uptake of [-_H}5-hydroxytryptamine ([3H]5-HT), and about 7-fold and 10-fold less potent than PCA at inhibiting synaptosomal uptake of [3H]dopamine and [3H]norepinephrine, respectively. In drug discrimination assays, MTA was nearly equipotent to PCA in animals trained to discriminate saline from 3,4-methylenedioxymethamphctamine (MDMA), or two related analogues S-(+)-N-methyl-l-(l,3-benzodioxol-5-yl)-2-butana- mine (S-MBDB) or 5-methoxy-6-methyl-2-aminoindan (MMAI). MTA caused dose-dependent increases of tritium cffiux from superfused rat frontal cortex slices preloaded with ['_H]5-HT. comparable to that induced by an equal molar concentration of PCA. Thc potential ncurotoxicity of MTA was examincd by measuring monoamine and metabolitc levels at one wcck following an acute dose. A 10 rog/kg dose of PCA caused a 70-90% decrease of cortical, hippocampal and striatal 5-HT and 5-hydoxyindoleacetic acid (5-HIAA) levels, while twice the molar dose of MTA (21.3 rog/kg) had m) effect. Thus. MTA is a potent, selective, semtonin releaser, apparently devoid of semtonin neurotoxic effects.
    [Show full text]